Replies to post #175913 on Anavex Life Sciences Corp (AVXL)

[OFP]

Trial results in 2019 will tell the entire story, won't they?

Trial results will certainly give a much much clearer picture though they seldom tell the entire story.

Until those results are available investors need to determine what they feel is the likelihood of success. Part of that determination would involve examination of the MOA and estimation of the strength with which it exerts that MOA relative to existing compounds for which we have better ideas of clinical effects. In this regard you've made recent declaratory statements without proffered evidence (regarding the uniqueness of the MOA and the strength of 2-73 S1R agonism relative to other S1R agonists). Please provide evidence or concede that there is none you are aware of.

As for trial timing...no results will be available in 2019 other than maybe the Rett preliminary study. PDD should be available in 2020 and the AD results are likely years after that under the current plan.

@Investor2014 You are certainly free to try to point out an error...but I do not feel one was made.